Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enpatoran in Active Cutaneous Lupus Erythematosus (ELOWEN-2)
NCT07470970Phase 3Not yet recruiting
- Sponsor
- EMD Serono
- Start
- Mar 2026
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enpatoran in cutaneous lupus erythematosus (CLE), systemic lupus erythematosus (SLE), sponsored by EMD Serono. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
enpatoran
03
Conditions
cutaneous lupus erythematosus (CLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07470970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07470970.